In 2025, the European Medicines Agency approved two antibodies for Alzheimer’s disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).